# Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT00602641** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 306 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00602641
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-02-29
- **Primary completion:** 2014-01-18
- **Final completion:** 2027-02-20
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602641, "Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00602641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*